Lung cancer survival in Germany: A population-based analysis of 132,612 lung cancer patients

We examine changes in survival and patient-, tumour- and treatment-related factors among resected and nonresected lung cancer patients, and identify subgroups with the largest and smallest survival improvements.National population-based data from the Cancer Registry of Norway, Statistics Norway and the Norwegian Patient Register were linked for lung cancer patients diagnosed during 1997–2011. The 1- and 5-year relative survival were estimated, and Cox proportional hazard regression, adjusted for selected patient characteristics, was used to assess prognostic factors for survival in lung cancer patients overall and stratified by resection status.We identified 34 157 patients with lung cancer. The proportion of histological diagnoses accompanied by molecular genetics testing increased from 0% to 26%, while those accompanied by immunohistochemistry increased from 8% to 26%. The 1-year relative survival among nonresected and resected patients increased from 21.7% to 34.2% and 75.4% to 91.5%, respectively. The improved survival remained significant after adjustment for age, sex, stage and histology. The largest improvements in survival occurred among resected and adenocarcinoma patients, while patients ≥80 years experienced the smallest increase.Lung cancer survival has increased considerably in Norway. The explanation is probably multifactorial, including improved attitude towards diagnostic work-up and treatment, and more accurate diagnostic testing that allows for improved selection for resection and improved treatment options.

Download Full-text

Improvement in Lung Cancer Survival: 6-Year Trends of Overall Survival at Hungarian Patients Diagnosed in 2011–2016

Pathology & Oncology Research ◽

10.3389/pore.2021.603937 ◽

2021 ◽

Vol 27 ◽

Author(s):

Krisztina Bogos ◽

Zoltan Kiss ◽

Lilla Tamási ◽

Gyula Ostoros ◽

Veronika Müller ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Cancer Survival ◽

Survival Rates ◽

Cancer Type ◽

Lung Cancer Patients ◽

First Time ◽

Lung Cancer Survival

Objective: Lung cancer is one of the most common cancers worldwide and its survival is still poor. The objective of our study was to estimate long-term survival of Hungarian lung cancer patients at first time based on a nationwide review of the National Health Insurance Fund database.Methods: Our retrospective, longitudinal study included patients aged ≥20 years who were diagnosed with lung cancer (ICD-10 C34) between January 1, 2011 and December 31, 2016. Survival rates were evaluated by year of diagnosis, patient gender and age, and morphology of lung cancer.Results: 41,854 newly diagnosed lung cancer patients were recorded. Mean age at diagnosis varied between 64.7 and 65.9 years during study period. One- and 5-year overall survival rates for the total population were 42.2 and 17.9%, respectively. Survival was statistically associated with gender, age and type of lung cancer. Female patients (n = 16,362) had 23% better survival (HR: 0.77, 95% confidence interval (CI): 0.75–0.79; p < 0.001) than males (n = 25,492). The highest survival rates were found in the 20–49 age cohort (5Y = 31.3%) and if the cancer type was adenocarcinoma (5Y = 20.5%). We measured 5.3% improvement (9.2% adjusted) in lung cancer survival comparing the period 2015–2016 to 2011–2012 (HR: 0.95 95% CI: 0.92–0.97; p = 0.003), the highest at females <60 year (0.86 (adjusted HR was 0.79), interaction analysis was significant for age and histology types.Conclusion: Our study provided long-term Lung cancer survival data in Hungary for the first time. We found a 5.3% improvement in 5-year survival in 4 years. Women and young patients had better survival. Survival rates were comparable to–and at the higher end of–rates registered in other East-Central European countries (7.7%–15.7%).

Download Full-text

Demographical differentials of lung cancer survival in Bangladeshi patients.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.10570 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. 10570-10570

Author(s):

Muhammad Rafiqul Islam ◽

ATM Kamrul Hasan ◽

Ferdous ara Begum ◽

Nazrina Khatun ◽

Md. Rafiqul Islam ◽

...

Keyword(s):

Lung Cancer ◽

Confidence Interval ◽

Cancer Patients ◽

Cancer Survival ◽

Survival Outcome ◽

Small Cell ◽

Hazard Ratio ◽

Lung Cancer Patients ◽

Impact On Survival ◽

Lung Cancer Survival

10570 Background: Lung Cancer is the leading cause of cancer-related mortality and most common cancer in worldwide with more than a million deaths annually. 20.8% cancer related death caused by lung cancer and more than half of lung cancer occurred in Asia. Differences In the epidemiology of lung cancer among the developing country may shed light on possible genetic and demographical influences on lung cancer survival. Demographic stratification of lung cancer patients of Bangladesh is remain unclear due of lack of data We tried to figure out the demographic pattern and its impact on survival in Bangladeshi lung cancer patient. Methods: Previously diagnosed primary lung cancer patients attending Medical Oncology department of National Institute of cancer research and Hospital, a tertiary care center of Bangladesh, between 2018 and 2019 were included. Demographic and clinical data were collected retrospectively from the medical records. Results: A total of 1868 consecutive patient (1580 males, 288females) diagnosed to have lung cancer; Mean age was 60 years which quite early compare to other countries. Older than 70-year age groups had worse survival outcome (hazard ratio 1.04: 95% confidence interval: 1.17–1.68). Below 50-year group had better outcome with standard adjuvant or palliative chemotherapy whereas older groups had better survival with sequential radiotherapy and chemotherapy or concurrent chemo radiation (Hazard Ratio 0.45; 95% confidence interval: 0.30–0.67). Sex was not a predicting factor for overall survival (Hazard ratios 1.04 95% confidence interval 0.89- 1.22, P = 0.621). But, Male had better treatment response than the female (Hazard ratio and 95% confidence interval: 0.51 and 0.42-0.61, P = < 0.001). Education level had significant impact on survival outcome (Hazard ratio 0.58 and 95% confidence interval: 0.47-0.71, P = < 0.001). Underweight group had worse survival than the normal BMI group (Hazard ratio1.18 and 95% confidence interval 1.05-1.31, P = 0.005). Having the Comorbid condition at the time of diagnosis had shorter survival (Hazard ratio 1.16 and 95% confidence interval 1.04-1.30 P = 0.007). Histological variation had no survival benefit among the squamous, small cell or other histological types (p = 0.214, 0.494, 0.658 respectively). But adenocarcinoma or small cell carcinoma had better treatment response outcome. Eastern Cooperative Oncology Group performance status (ECOG-PS) 4 had worse outcome (Hazard ratio 1.95, 95% confidence interval 1.37–2.79; P = < 0.001). Conclusions: The socio-demographic related survival in lung cancer needs to be fully elucidated because of its implication in the design of experimental protocols for targeted chemoprevention, early disease screening, molecular marker based staging, and individualized treatment. Due to its extraordinary disease burden and the international variability in demographic variables, the lung cancer requires continual monitoring.

Download Full-text

Improvement in lung cancer survival: Six-year survival analysis of patients diagnosed between 2011 and 2016 in Hungary.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e21582 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e21582-e21582

Author(s):

Krisztina Bogos ◽

Zoltan Kiss ◽

Lilla Tamási ◽

Gyula Ostoros ◽

Veronika Judit Dr Szabone Dr Muller ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Cancer Survival ◽

Survival Rates ◽

Insurance Fund ◽

Cancer Type ◽

Lung Cancer Patients ◽

Icd 10 ◽

Lung Cancer Survival

e21582 Background: Lung cancer is one of the most common cancers worldwide, however, 5-year survival is poor, only 10-20% of pataients survive this period. To date, no long-term study has been conducted to evaluate long-term survival rates in Hungary. Therefore, the objective of our study was to assess the 6-year survival of lung cancer patients (ICD-10 C34) based on a nationwide review of the National Health Insurance Fund (NHIF) database. Methods: Our retrospective, longitudinal study included patients aged ≥20 years who were diagnosed with lung cancer (ICD-10 C34) between 1 January 2011 and 31 December 2016. Screening period was set for 2009-2010. Patients with other cancer-related ICD-10 codes 6 months before or 12 months after lung cancer diagnosis and those who received any anticancer treatment different from lung cancer protocols were excluded. Survival rates were evaluated according to year of diagnosis, patient gender and age, and morphology of lung cancer and main treatment type. Results: 41,854 newly diagnosed lung cancer patients were recorded. Mean age at diagnosis varied between 64.66 and 65.88 years during study period. One- and 5-year crude survival rates for the total population were 42.23% and 17.85%, respectively. Survival was significantly associated with gender, age and type of lung cancer based on statistical association. Female patients (n = 16,362) had 23% better survival (HR: 0.77 CI95% 0.75-0.79; p < 0.001) than males (n = 25,492). The highest survival rates were found in the 20–49 age cohort (5Y = 31.3%) and if the cancer type was adenocarcinoma (5Y = 20.48%). We measured 5.3 % improvement in lung cancer survival between cases diagnosed in 2015-2016 vs. 2011-2012 (HR: 0.947 CI95% 0.92-0.97; p = 0.003). Survival of those lung cancer patients, whom had surgery in first line treatment without adjuvant therapy (3,120) reached 64.18%, those with adjuvant treatment (n = 2,675) 54.47% 5 year survival, while patients with chemotherapy (n = 11,780) had only 7.9% crude survival. Conclusions: Our study provided long-term LC survival data in Hungary for the first time. We found a 6% improvement in survival by the end of the study period in females and in the younger age groups. Survival rates were comparable to – and at the higher end of – rates registered in other East-Central European countries. Better survival rate of females could be attributed to a higher incidence rate of adenocarcinoma in women. Lung cancer patients diagnosed in early stage had 7-8 times better survival than those found in late stage.

Download Full-text